History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders
I. Menéndez-Miranda, Leticia García-Álvarez, M. García-Portilla, L. González-Blanco, Pilar A. Sáiz, Julio Bobes
European Addiction Research March 21, 2019 DOI: 10.1159/000497317 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Naturalistic cross-sectional study Peer reviewed |
|---|---|
| Sample size | 123 |
| Population | Clinically stable outpatients with schizophrenia spectrum disorders |
| Measures | Positive and Negative Syndrome Scale, Hamilton Depression Rating Scale, Clinical Global Impression (CGI), Personal and Social Performance scale, Screen for Cognitive Impairment in Psychiatry (SCIP) |
| Topics | Cannabis |
| Key findings | Lifetime cannabis use was associated with better working memory and processing speed but worse real-world functioning in socially useful activities among patients with schizophrenia spectrum disorders, with differences persisting after adjustment for antipsychotic doses. Past-year cannabis users had worse mood, though this association disappeared after dose adjustment. |
Abstract
Background: Data on associations between cannabis use and psychopathology, cognition and functional impairment in schizophrenia spectrum disorders (SSD) is controversial.
Objectives: To examine the effect of cannabis on psychopathology, cognition and real-world functioning in SSD patients.
Method: Naturalistic cross-sectional study, 123 clinically stable SSD outpatients. Assessment: demographic and clinical data, psychometric evaluation: Positive and Negative Syndrome, Hamilton Depression Rating, Clinical Global Impression (CGI), Personal and Social Performance and Screen for Cognitive Impairment in Psychiatry (SCIP) scales. Patients were classified as cannabis user patients (CUP) and non cannabis user patients (NCUP) according to self-report, both lifetime and last year. Statistical analysis: chi-square, Student t test, ANOVA (Duncan post hoc), and general linear model analysis for adjusting for antipsychotic doses.
Results: Mean age 40.75, 66.7% male, single (66.7%), prior hospital admissions 2.75, mean length of illness 13.85 years. 53.7% were lifetime cannabis users and 8.9% last year users. Lifetime CUP had more hospitalizations (p = 0.013) at a younger age (p = 0.002), and showed better cognitive functioning globally (CGI-C: p = 0.045) and on working memory and processing speed (SCIP-2: p = 0.039; SCIP-5: p = 0.033) and worse functioning in socially useful activities (p = 0.014) than NCUP. All these differences remained after adjusting for antipsychotic doses. Last year cannabis users had worse mood (Hamilton Depression Rating Scale 9.66 vs. 5.64; p = 0.002), but this difference disappears when adjusting for antipsychotic doses.
Conclusions: Lifetime cannabis use is associated with better working memory and processing speed and worse real-world functioning in the area of socially useful activities in patients with schizophrenia-related disorders. Clinicians should, therefore, be aware of it to provide patient-centred care in their daily clinical practice.
Comparable studies
Other cross-sectional and survey studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabis use before age 15 and subsequent executive functioning 104 chronic cannabis users (49 early-onset before age 15, 55 late-onset after age 15)... | 2011 | Observational cross-sectional study | n = 148 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Online survey respondents | 2020 | Cross-sectional survey | |
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study Users of hallucinogenic drugs who completed a web-based questionnaire | 2010 | Cross-sectional survey | n = 600 |
| Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Adults recruited from the MAPS website and newsletter, most reporting use of various... | 2012 | Cross-sectional survey | n = 337 |
Citations in the library
Cited by 5
- Consumo de cannabis y alteraciones cognitivas en esquizofrenia y primeros episodios psicóticos Adicciones April 1, 2019
- Impaired mnemonic pattern separation associated with PTSD symptoms paradoxically improves with regular cannabis use npj Mental Health Research April 24, 2025
- Cannabis use and cognitive biases in people with first-episode psychosis and their siblings Psychological Medicine November 1, 2024
- Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts Schizophrenia Research July 30, 2024
- Introduction to JINS Special Issue: Clarifying the Complexities of Cannabis and Cognition Journal of the International Neuropsychological Society July 1, 2021